

1 ENGROSSED SENATE  
2 BILL NO. 927

3 By: Hicks of the Senate

4 and

5 Munson of the House

6 An Act relating to the state Medicaid program;  
7 amending 63 O.S. 2021, Section 5030.1, which relates  
8 to the Medicaid Drug Utilization Review Board;  
modifying appointment procedure for certain members;  
updating statutory language; and providing an  
effective date.

10  
11 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

12 SECTION 1. AMENDATORY 63 O.S. 2021, Section 5030.1, is  
13 amended to read as follows:

14 Section 5030.1. A. There is hereby created within the Oklahoma  
15 Health Care Authority the Medicaid Drug Utilization Review Board,  
16 which shall be responsible for the development, implementation and  
17 assessment of retrospective and prospective drug utilization  
18 programs under the direction of the Authority.

19  
20 B. The Medicaid Drug Utilization Review Board shall consist of  
21 ten (10) members appointed by the administrator of the Authority as  
22 follows:

1       1. Four physicians, licensed and actively engaged in the  
2 practice of medicine or osteopathic medicine in this state, of  
3 which:

- 4           a. three shall be physicians, each of whom is chosen from  
5           a list of not less than ~~six~~ three names submitted by  
6           the Oklahoma State Medical Association, and  
7           b. one shall be a physician chosen from a list of not  
8           less than two names submitted by the Oklahoma  
9           Osteopathic Association;

10       2. Four licensed pharmacists actively engaged in the practice  
11 of pharmacy, chosen from a list of not less than six names submitted  
12 by the Oklahoma ~~Pharmaceutical~~ Pharmacists Association;

13       3. One person representing the lay community, who shall not be  
14 a physician or a pharmacist, but shall be a health care professional  
15 with recognized knowledge and expertise in at least one of the  
16 following:

- 17           a. clinically appropriate prescribing of covered  
18           outpatient drugs,  
19           b. clinically appropriate dispensing and monitoring of  
20           covered outpatient drugs,  
21           c. drug use review, evaluation and intervention, and  
22           d. medical quality assurance; and

23       4. One person representing the pharmaceutical industry who is a  
24 resident of ~~the State of Oklahoma~~ this state, chosen from a list of

1 not less than two names submitted by the Pharmaceutical Research and  
2 Manufacturers of America. The member representing the  
3 pharmaceutical industry shall be prohibited from voting on action  
4 items involving drugs or classes of drugs.

5 C. Members shall serve terms of three (3) years, except that  
6 one physician, one pharmacist and the lay representative shall each  
7 be initially appointed for two-year terms in order to stagger the  
8 terms. In making the appointments, the administrator shall provide,  
9 to the extent possible, for geographic balance in the representation  
10 on the Medicaid Drug Utilization Review Board. Members may be  
11 reappointed for a period not to exceed three three-year terms and  
12 one partial term. Vacancies on the Medicaid Drug Utilization Review  
13 Board shall be filled for the balance of the unexpired term from new  
14 lists submitted by the entity originally submitting the list for the  
15 position vacated.

16 D. The Medicaid Drug Utilization Review Board shall elect from  
17 among its members a chair and a ~~vice-chair~~ vice chair who shall  
18 serve one-year terms, provided they may succeed themselves.

19 E. The proceedings of all meetings of the Medicaid Drug  
20 Utilization Review Board shall comply with the provisions of the  
21 Oklahoma Open Meeting Act and shall be subject to the provisions of  
22 the Administrative Procedures Act.

23 F. The Medicaid Drug Utilization Review Board may advise and  
24 make recommendations to the Authority regarding existing, proposed

1 and emergency rules governing retrospective and prospective drug  
2 utilization programs. The Oklahoma Health Care Authority Board  
3 shall promulgate rules pursuant to the provisions of the  
4 Administrative Procedures Act for implementation of the provisions  
5 of this section.

6 SECTION 2. This act shall become effective November 1, 2025.

7 Passed the Senate the 17th day of March, 2025.

8

---

9 Presiding Officer of the Senate

10

11 Passed the House of Representatives the \_\_\_\_ day of \_\_\_\_\_,  
12 2025.

13

---

14 Presiding Officer of the House  
15 of Representatives